During late spring and early summer, the U.S. Food and Drug Administration (FDA) approved four new molecularly targeted therapeutics—alpelisib (Piqray), polatuzumab vedotin-piiq (Polivy), selinexor (Xpovio), and darolutamide (Nubeqa)—for treating certain patients with a wide array of cancer types. Molecularly targeted therapeutics are the cornerstone of precision oncology. So, this flurry of approvals highlights that progress in this important area of cancer care is continuing unabated.Read More
The AACR Annual Meeting 2019 features the theme “Integrative Cancer Science • Global Impact • Individualized Patient Care.” That theme provided the structure for Monday’s plenary session, when cancer researchers representing three continents, four cancer types, and diverse areas of interest took the stage.Read More
Non-Hispanic black men in the United States are much more likely to develop prostate cancer and to die from the disease than their non-Hispanic white counterparts. Many factors contribute to this striking disparity, including access to and use of health care, social and economic status, and biology. As discussed by Steven R. Patierno, PhD, and colleagues in a recent perspective article in the AACR journal Clinical Cancer Research, alternative RNA splicing is one biological factor contributing to prostate cancer disparities.Read More
Rates of diabetes in the United States are increasing. According to statistics from the Centers for Disease Control and Prevention (CDC), an estimated 23 million Americans received a diagnosis of diabetes in 2015, in contrast to 1.6 million Americans in 1958. Our risk for diabetes increases as we age; over 25 percent of those ages 65 or older had diabetes in 2015, according to the CDC.
Diabetes is a risk factor for several types of cancer, including liver, pancreatic, and endometrial cancers. While this association is complex, some possible biological links include insulin resistance and hyperglycemia.
Previous work to understand the relationship between hyperglycemia and prostate cancer risk and mortality have yielded mixed results. A recent study published in Cancer Prevention Research evaluated whether hyperglycemia, as measured through multiple biomarkers, is associated with prostate cancer incidence and mortality.Read More
For the third year running, the American Association for Cancer Research (AACR) has been selected as the beneficiary of the 18th annual Party with a Purpose, a cause-driven gala in Philadelphia that supports lifesaving cancer research. Funds raised at this year’s event will be dedicated to research focused on prostate cancer. This common cancer is estimated to affect nearly 165,000 men in 2018, according to recent statistics.Read More
Last week, the U.S. Food and Drug Administration (FDA) approved the antihormone agent apalutamide (Erleada) for treating men with nonmetastatic prostate cancer that has stopped responding to standard antihormone treatments.Read More
Prostate cancer is one of the most common cancers diagnosed in the United States. About one-third of men diagnosed with prostate cancer have a tumor that grows very slowly, making it very unlikely that the disease will progress to become a clinical problem. Characterizing new ways to identify these cancers is an area of active research investigation.Read More
Next to skin cancer, prostate cancer is the most diagnosed cancer among men in the United States. Data from the Surveillance, Epidemiology, and End Results (SEER) Program indicate that over …Read More
The U.S. Preventive Services Task Force (USPSTF) released draft recommendations April 11 suggesting that doctors inform men ages 55 to 69 of the potential benefits and harms of prostate-specific antigen (PSA) blood testing to screen for prostate cancer. The draft says the decision to be screened is an individual one that should be made after consulting with a physician.Read More
A team of mathematicians are designing an app that could help predict the likelihood of prostate cancer relapse.Read More